2126
vs
H
Hang Seng (Hong Kong)
2126
Over the past 12 months, JW (Cayman) Therapeutics Co Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +109% compared to the Hang Seng (Hong Kong)'s +29% growth.
Stocks Performance
2126 vs Hang Seng (Hong Kong)
Performance Gap
2126 vs Hang Seng (Hong Kong)
Performance By Year
2126 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JW (Cayman) Therapeutics Co Ltd
Glance View
JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.